Comorbidities in interstitial lung diseases release_hjrhoiesqvhf5e5gyh2k4myx6q

by George A. Margaritopoulos, Katerina M. Antoniou, Athol U. Wells

Published in European Respiratory Review by European Respiratory Society (ERS).

2017   Volume 26, Issue 143, p160027

Abstract

Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal reflux, pulmonary hypertension, lung cancer, cardiovascular diseases, and obstructive sleep apnoea, can pre-exist or develop at any time during the course of the disease and, if unidentified and untreated, may impair quality of life, impact upon the respiratory status of the patients, and ultimately lead to disease progression and death. Therefore, early identification and accurate treatment of comorbidities is essential.
In text/plain format

Archived Files and Locations

application/pdf  351.9 kB
file_yg7kmst5zbhsnn34ctihljbhsi
web.archive.org (webarchive)
err.ersjournals.com (web)
application/pdf  351.9 kB
file_maoj2odl6nchphkwtarlysd2yq
web.archive.org (webarchive)
err.ersjournals.com:80 (web)

Web Captures

https://err.ersjournals.com/content/26/143/160027.full
2020-08-14 04:53:58 | 51 resources
webcapture_ufbg6khtmbgwpavp5p4nocrwsa
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2017-01-03
Language   en ?
DOI  10.1183/16000617.0027-2016
PubMed  28049126
PMC  PMC9488735
Wikidata  Q30239848
Container Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:  0905-9180
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: b6e23734-3d32-4f37-ac9b-8b5b463022b7
API URL: JSON